The antibody MPDL3280A, which blocks the protein PD-L1, resulted in tumor shrinkage in slightly over half of tested patients with advanced bladder cancer.
Among premenopausal women with early stage, HR-positive breast cancer, the addition of ovarian suppression to tamoxifen reduced breast cancer recurrence.
The International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium.
Pembrolizumab was well tolerated and yielded durable responses in patients with metastatic triple-negative breast cancer, according to recent trial data.
A new drug that targets common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), and a type of the mutation responsible for treatment resistance, has shown promising results in a phase I/II clinical trial.
The first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1 has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation.
The anticancer drug galeterone has proved successful in lowering prostate-specific antigen levels in men with castration-resistant prostate cancer (CRPC).
A method to determine which patients with ovarian cancer are more likely to respond well to the new anticancer drug rucaparib has been discovered.
Previously, patients with advanced colorectal cancer driven by a mutated version of the BRAF gene have had limited treatment options, but results from a multicenter clinical trial suggest a new option.
Patients with B-cell non-Hodgkin lymphomas and advanced solid tumors have responded to a new drug that is being tested for the first time in humans in a phase I clinical trial.
Latina patients with breast cancer had much more awareness of clinical trials versus women who received the typical information.
An investigational personalized cellular therapy was found to have achieved remission in some 90% of children and adults with acute lymphoblastic leukemia (ALL) tested.
A new drug breakthrough could extend the life of people living with glioblastoma, the most aggressive type of brain cancer.
A new drug in development, known as DTP3, has killed myeloma cells in laboratory tests in human cells and mice.
Clinical trials could benefit from a greater number of participants with a dedicated cooperative network to support rural community cancer centers.
A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.
Approximately one fifth of patients with malignant pleural mesothelioma have cancer cells that express a protein called programmed cell-death ligand 1 (PD-L1), which has been associated with poorer outcomes.
Targeting BRAF V600E/K mutation-positive melanoma with dabrafenib in combination with trametinib achieves longer overall survival and impoved response rates, compared to treatment with vemurafenib alone.
The BRAF inhibitor dabrafenib has significant antitumor activity in patients with advanced BRAF V600E mutant non-small cell lung cancer (NSCLC) whose disease has progressed after chemotherapy, according to phase II data.
Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study confirms use of trastuzumab for HER2-positive breast cancerOctober 07, 2014
The use of trastuzumab (Herceptin) as the standard-of-care treatment for HER2-positive breast cancer has been supported by the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study.
An experimental regimen of once-weekly breast irradiation after lumpectomy provides more convenience to patients at less expense, and results in better completion rates of prescribed radiation treatment.
The experimental drug nintedanib, in combination with standard paclitaxel chemotherapy, caused a total remission of tumors in half of patients with early stage HER2-negative breast cancer.
Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all trial steps are most likely to undergo a biopsy at the end of the trial, according to recent research.
Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study.
A new therapeutic combination to combat resistant sarcomas has shown promise in a trial.
An experimental immunotherapy agent was placed on the US Food and Drug Administration's fast track to market approval after overwhelmingly positive results were seen in patients with leukemia. In early trials, 89% of patients who received the personalized immunotherapy known as CTL019 saw their cancers disappear.
Surgical biopsy is safe for certain late-stage lung cancer patients and could improve their chances of getting treated with newer types of drugs that target cancer-related genetic mutations.
Results of a phase I clinical trial of a vaccine therapy for pancreatic cancer indicate the treatment is well tolerated; in addition, it suggests that the vaccine stabilizes the disease for a period of time.
A study using a 5-year LDCT screening protocol showed good adherence and patient survival outcomes in persons at high risk of developing lung cancer.
An increasingly complex environment for cancer care and research highlights the need to streamline access to cancer information, especially clinical trials.
- Two major studies strengthen case for prostate cancer drug before chemotherapy
- Single therapy offers improved survival in younger patients with limited brain metastases
- Use of adjuvant systemic therapy increasing for gastrointestinal stromal tumors (GIST)
- People who drink 3-5 cups of coffee per day less likely to develop clogged arteries
- Statin hyporesponders may have blocked arteries
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|